The growing dynamics in penetrating the market will even increase further next year according to SastoMed: Overall another 5,000 doctors and 500 hospitals are planned to be gained to regularly administer Granulox in Germany alone. At the same time internationalizing the business will move up on the agenda. The current positive experiences made in Germany will among others also lead to entrusting the leadership in operating sales in Mexico to SastoMed - for the sake of a consistent market appearance and in accordance with the Mexican partners. In parallel, market entry in Austria, the United Kingdom and Turkey are under preparation. Additional European markets are planned to be addressed in 2014. The international business will be directed by a top marketing and sales manager with international track record. More details will be disclosed after the signing of the final articles of employment.
Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, was impressed by these preliminary statements: "We at Sangui are particularly proud of the fact that our yearlong focus on this technology was the right move. We are especially glad to obtain such a positive response from competent experts, who confirm our great expectations. And we are delighted to see how many patients now experience the benefits of Granulox treatment. Our strategic decision to transfer marketing and sales of the Sangui developed technology to highly professional partners has proven to be the best possible choice. We support this intense growth course also on the financial side and intend to push-start the international activities. We can foresee that beginning end of this year but increasingly so over the years to come the positive cash flow from the joint venture company will more than justify our decisions."
Further inquiry note:
Dr. Joachim Fleing
|SOURCE Sangui Bio Tech International Inc.|
Copyright©2012 PR Newswire.
All rights reserved